Abstract
Dupilumab, a human mAb, blocks the shared receptor component for IL-4/13, key and central drivers of type 2 inflammation. In VOYAGE (NCT02948959), dupilumab 100/200mg vs placebo every 2 weeks for 52 weeks reduced severe asthma annualized exacerbation rate (AER) and improved percent predicted pre-bronchodilator FEV1 (ppFEV1) in children aged 6-11 years with uncontrolled, moderate-to-severe asthma. We evaluated the predictive value of baseline blood eosinophil and FeNO levels as biomarkers for dupilumab response.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
